Epirubicin, Cisplatin, Capecitabine

DRUG2 trials

Sponsors

Royal Marsden NHS Foundation Trust, AIO-Studien-gGmbH

Conditions

Gastroesophageal Junction NeoplasmsOesophageal CarcinomaStomach Neoplasms

Phase 2

Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus

CompletedNCT00220129

Royal Marsden NHS Foundation TrustOesophageal Carcinoma

Start: 2002-11-30Updated: 2009-12-16

ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction

CompletedNCT01234324

AIO-Studien-gGmbHGastroesophageal Junction Neoplasms, Stomach Neoplasms

Start: 2010-10-31End: 2017-08-31Updated: 2018-01-23

Related Papers

Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).

2018-03-2034 citations

Perioperative chemotherapy with ECX +/- panitumumab in locally advanced gastroesophageal adenocarcinomas (GEA): A randomized study of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the German Cancer Society.

Journal of Clinical Oncology2015-01-203 citations